Abcam, ab300151, Anti-CD79a antibody [EPR26537-114] (BSA and Azide free)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CD79A antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, IHC-Fr, IP and reacts with Rat, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR26537-114,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:WB, ICC/IF, IP, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD79a also known as Ig-alpha or MB-1 is a component of the B cell antigen receptor (BCR) complex. It is a transmembrane protein with a molecular mass of approximately 47 kDa. CD79a is part of a heterodimer with CD79b and is mainly expressed on the surface of B lymphocytes. This protein plays a critical mechanical role in signaling transduction through the BCR by associating with membrane-bound immunoglobulin molecules helping to initiate the immune response upon antigen binding.
Biological function summary
This protein acts as an essential mediator in the immune system. CD79a together with CD79b forms part of the BCR complex critical for B cell development and maturation. The BCR complex activates signaling cascades that influence B cell fate decisions such as proliferation differentiation and apoptosis. By transmitting signals from the BCR CD79a helps regulate these cellular functions necessary for efficient immune defense.
Pathways
CD79a plays a pivotal role in the B cell receptor signaling pathway. This pathway involves signaling molecules such as spleen tyrosine kinase (SYK) and phosphoinositide 3-kinase (PI3K) which are activated upon BCR engagement. CD79a acts in concert with other proteins including CD79b and the IgM receptor facilitating downstream signaling cascades that ensure proper B cell responses. Its role is important for linking extracellular antigen recognition to intracellular signaling events.
CD79a is significant in conditions like B cell lymphomas and certain immunodeficiencies. Abnormal expression or mutations in CD79a are associated with some types of non-Hodgkin lymphoma. The protein's interaction with CD79b is particularly relevant as alterations in these proteins' function or expression can impact B cell development and lead to pathogenesis in lymphoproliferative disorders. Consequently CD79a serves as an important biomarker and potential therapeutic target in these diseases.